We are live on ! Find out more
ANVS icon

Annovis Bio

23 hedge funds and large institutions have $11.6M invested in Annovis Bio in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

21% more capital invested

Capital invested by funds: $9.6M → $11.6M (+$1.99M)

5% more funds holding

Funds holding: 2223 (+1)

0.44% more ownership

Funds ownership: 8.78%9.22% (+0.44%)

Holders
23
Holders Change
+1
Holders Change %
+4.55%
% of All Funds
0.37%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
6
Reduced
4
Closed
4
Calls
Puts
Net Calls
Net Calls Change

ANVS Hedge Fund Activity: Q1 2023 in Review

23 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q1 2023, worth a combined $11.6M — up 21% from $9.6M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ANVS positions and 4 closed out — a net gain of 1 holder — while 6 added to existing stakes and 4 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $240K. The largest seller was Morgan Stanley, cutting an estimated $451K.

  • 23 institutional investors held Annovis Bio (ANVS) as of Q1 2023, up from 22 in Q4 2022.
  • Funds reported $11.6M of Annovis Bio stock for Q1 2023, up 21% quarter-over-quarter.
  • 5 funds opened new Annovis Bio positions in Q1 2023 and 4 closed out, a net change of +1 holder.
  • The largest Annovis Bio buyer in Q1 2023 was Jane Street, an estimated $240K added.
  • The largest Annovis Bio seller in Q1 2023 was Morgan Stanley, an estimated $451K sold.

Based on aggregated 13F filings for Q1 2023.